Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.Manufacturer Supply Perindopril Erbumine Related Intermediates L-Octahydroindole-2-Carboxylic Acid CAS 80875-98-5 (S)-(-)-Indoline-2-Carboxylic Acid CAS 79815-20-6 (±)-Indoline-2-Carboxylic Acid CAS 78348-24-0 N-[(S)-Ethoxycarbonyl-1-Butyl]-(S)-Alanine CAS 82834-12-6 Perindopril Erbumine CAS 107133-36-8| Item | Specifications |
| Appearance | White to Off-White Crystalline Powder |
| Identification | HNMR; HPLC |
| Purity / Analysis Method | >99.0% (HPLC) |
| Melting Point | 256.0~265.0℃ |
| Water (K.F) | ≤0.50% |
| Residue on Ignition | ≤0.50% |
| Specific Rotation [α]D20 | -45.0°～-50.0° (C=1, CH3OH) |
| Total Impurities | <1.00% |
| Heavy Metals (as Pb) | ≤20ppm |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Perindopril Erbumine (CAS: 107133-36-8) |
Description:
Specifications:
Package & Storage:
| Chemical Name | L-Octahydroindole-2-Carboxylic Acid |
| Synonyms | (2S,3aS,7aS)-Octahydroindole-2-Carboxylic Acid; (2S,3aS,7aS)-Octahydro-1H-Indole-2-Carboxylic Acid; Perindopril USP Related Compound A |
| CAS Number | 80875-98-5 |
| CAT Number | RF-PI1490 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C9H15NO2 |
| Molecular Weight | 169.22 |
| Density | 1.135±0.06 g/cm3 |
| Solubility | Soluble in Methanol and Water |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
L-Octahydroindole-2-Carboxylic Acid (CAS: 80875-98-5) is an intermediate in the synthesis of Perindopril (CAS: 82834-16-0) and Perindopril Erbumine (CAS: 107133-36-8). Perindopril Erbumine is a potent and long-acting angiotensin converting enzyme inhibitor, can lower the peripheral vascular resistance with cardiac output and heart rate unchanged. Perindopril shares the indications of ACE inhibitors as a class, including essential hypertension, stable coronary artery disease (reduction of risk of cardiac events in patients with a history of myocardial infarction and/or revascularization) and treatment of symptomatic heart disease or heart failure. In addition, the Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS) found that perindopril reduces the risk of stroke in both hypertensive and normotensive individuals with a history of stroke or transient ischemic attack.
